BMP7 ELISA kit
- Known as:
- BMP7 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-BMP7-Mu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- BMP7 ELISA kit
Related genes to: BMP7 ELISA kit
- Gene:
- BMP7 NIH gene
- Name:
- bone morphogenetic protein 7
- Previous symbol:
- -
- Synonyms:
- OP-1
- Chromosome:
- 20q13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1991-06-05
- Date modifiied:
- 2016-10-05
Related products to: BMP7 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: BMP7 ELISA kit
- Osteoarthritis (OA) primarly involves the degradation of joint cartilage and requires new treatments. REJENERA, a newly developed nutraceutical formula against OA, contains primarily olive leaf bioflavonoids ( ZeyEX, quercetin and luteolin), S-allylcysteine, palmitoylethanolamide, L-proline, hyaluronic acid and boron. This study focuses on the efficacy of REJENERA in treating knee OA and aims to compare it with ZeyEX, NPROC (a product obtained by combining collagen-rich eggshell membrane with olive leaf extract), and IBUPROFEN in a rat OA model. OA was established by intra-articular injection of monosodium iodoacetate (MIA; 3 mg) into the right knee joints. Rats were either left untreated or treated orally for 12 weeks with REJENERA, ZeyEX, NPROC (300 mg/kg/day) or IBUPROFEN (3 mg/kg/day). MIA injection produced joint degeneration including increased fissure-index, osteophyte-score, and OARSI-score, joint swelling, synovial inflammation, proteoglycan loss, and decreased cartilage thickness. These histopathological abnormalities were partially but significantly alleviated by REJENERA and other treatments. Only ZeyEX significantly inhibited the OA-induced increase in IL-1β, IL-6, IL-10 and LPO in serum, and IL-6, TNF-α, and IFN-γ in synovial fluid. While increases in MMP-3 and MMP-9 were reduced with all treatments, MMP-13 was inhibited only by REJENERA. ZeyEX increased IL-2, NPROC increased IL-6, and IBUPROFEN inhibited IL-10. All treatments improved TIMP-1 levels; however, TXNIP was more significantly inhibited by ZeyEX, and NLRP3 by REJENERA. REJENERA's anti-OA effects are accompanied by an increase in cartilage anabolic factors (Ki-67, type-II collagen, BMP-7) and inhibition of apoptosis. REJENERA offers a promising multi-targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling axis, and reducing oxidative stress. - Source: PubMed
Publication date: 2026/07/06
Tepedelenlioglu Huseyin EmreElmazoglu ZubeyirSaribas Sanem GulistanTutuncu YildizCeylan Asli FKarasu Çimen - Formimidoyltransferase cyclodeaminase () is a folate-metabolizing enzyme involved in histidine catabolism and intracellular folate homeostasis. Although has been implicated in cancer progression and epithelial-mesenchymal transition (EMT) in several malignancies, its oncological role in colorectal cancer (CRC) remains unclear. This study investigated the biological and clinical significance of in CRC. - Source: PubMed
Tanaka KenshiroUmeda ShinichiHattori NorifumiKishida TakayoshiNakanishi KokiTanaka HaruyoshiShimizu DaiTakami HidekiHayashi MasamichiKanda MitsuroTanaka ChieNakayama GoroFujiwara MichitakaKodera Yasuhiro - Animal models of enhanced fertility are rare, as most genetically modified mouse models with reproductive phenotype display subfertility or infertility. Here we describe the ovarian phenotype of the Dummerstorf line 2 (FL2) mouse strain, which exhibits high fertility and has been selectively bred for increased fertility over more than 190 generations. This long-term selection, outbred mouse line almost doubled the litter size to 21.5 (FL2) compared to 11.3 (unselected control line, ctrl) without showing any signs of growth retardation in the offspring. Here we show that FL2 females ovulate 25.0 oocytes per cycle compared to 13.2 in ctrl. FL2 mice remain in the estrus phase for a shorter period during a 12-day observation period. Follicle-stimulating hormone (FSH) levels are decreased, both in estrus and diestrus, compared to ctrl, whereas Luteinizing hormone (LH) levels are unaffected. The mRNA expression levels in the pituitary gland correspond to the gonadotropin levels in the blood. Progesterone levels are decreased in estrus in FL2. Hypothalamic expression levels of Gonadotropin-releasing hormone (GnRH) are decreased in diestrus. Holistic gene expression analysis indicates complex and differential regulation in estrus and diestrus in ovaries of FL2 compared to ctrl. Especially genes of the TGF-β pathway (such as Bmp3, Bmp7, Inhba) and the Wnt pathway (such as Sfrp4, Mkrn1) are differentially expressed in ovaries of FL2 females. These data indicate that reduced activity of the hypothalamic-pituitary-gonadal axis (in particular, lower levels of GnRH, FSH and progesterone), combined with altered gene transcription in the ovaries, leads to higher ovulation rates in order to achieve the breeding objective of improved fertility. - Source: PubMed
Publication date: 2026/06/29
Ludwig Carolin L MBohleber SimonBaufeld AnjaWirth Eva KLanghammer MartinaSchweizer UlrichMichaelis MartenWeitzel Joachim M - Anhedonia, a core symptom of major depressive disorder (MDD), is closely associated with cognitive deficits and elevated suicide risk. This study aimed to investigate the relationship between inflammatory markers and anhedonia. - Source: PubMed
Publication date: 2026/06/27
Yuan ShitingJing PanZhang XueyingChen PengTian QingSun ChaoZhang GuangyaZhang XiaobinSun Wenxi - This study investigated the synergistic anti-arthritic effects of Wenyang Yishen Tongluo Prescription (TLP) combined with bone marrow mesenchymal stem cells (BMSCs) in rheumatoid arthritis (RA). A collagen-induced arthritis (CIA) rat model was established, and animals were divided into groups receiving TLP, BMSCs, or combination therapy. Network pharmacology identified IL-6 as a core target of TLP, which was further validated by molecular docking and cellular thermal shift assay (CETSA). The combination therapy reduced arthritis index score by 34.41% compared with the model group, alleviated synovial hyperplasia and fibrosis, synergistically downregulated autoantibody rheumatoid factor (RF), pro-inflammatory factors (TNF-α, MMP-9, VEGFA), and bone-resorptive factor RANKL, while upregulating bone-protective factors (BMP-7, OPG) and immunosuppressive molecules (TGF-β1, PD-1, FOXP3). Mechanistically, TLP restored BMSC function by inhibiting IL-6 and its downstream phosphorylation of NF-κB, STAT3, and Akt pathways, as demonstrated by IL-6 overexpression experiments. These findings demonstrate that TLP combined with BMSCs synergistically ameliorates the inflammatory microenvironment, restores immune balance, and reduces bone damage in RA by targeting IL-6 and its downstream signaling, offering a safe and effective integrative treatment strategy. - Source: PubMed
Publication date: 2026/06/25
Su RongYin ShiyunGu LingliLiu WeichaoYan WeitianZhou WeijianPeng Jiangyun